LettersStroke and Bleeding Risks in NOAC- and Warfarin-Treated Patients With Hypertrophic Cardiomyopathy and Atrial Fibrillation
Under an Elsevier user license
open archive
Cited by (0)
Please note: Dr. Gersh has consulted for Janssen Pharmaceuticals. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
© 2016 by the American College of Cardiology Foundation